Welcome to our dedicated page for Maxcyte news (Ticker: MXCT), a resource for investors and traders seeking the latest updates and insights on Maxcyte stock.
MaxCyte, Inc. (MXCT) pioneers advanced cell engineering through its proprietary Flow Electroporation technology, enabling breakthroughs in gene therapy and biopharmaceutical development. This dedicated news hub provides investors and industry professionals with essential updates on MXCT’s strategic initiatives, financial performance, and scientific advancements.
Access timely press releases covering regulatory milestones, partnership announcements, and technology innovations. Our curated collection includes earnings reports, clinical trial updates, and analyses of MXCT’s role in advancing next-generation cell therapies. The platform serves as a critical resource for tracking the company’s impact on precision medicine and scalable therapeutic manufacturing.
Discover updates about MXCT’s ExPERT platform deployments, licensing agreements with biotech innovators, and expansions in global research collaborations. Content is organized for quick scanning while maintaining technical accuracy, ensuring relevance for both casual observers and specialized analysts.
Bookmark this page for streamlined access to verified MXCT developments. Combine our news feed with Stock Titan’s financial tools to monitor how MaxCyte’s cell engineering leadership translates into long-term market positioning.
MaxCyte announced preliminary revenue results for Q4 and full year 2022, reporting expected total revenue of approximately $44.3 million, up 31% from 2021. Q4 revenue is projected at $12.4 million, reflecting a 22% increase compared to Q4 2021. The installed base of instruments surpassed 600, compared to over 500 in 2021. MaxCyte's guidance for 2023 indicates total revenue growth of 21% to 26% year-over-year, with approximately $6 million from SPL program-related revenue. The company ended 2022 with 18 SPL partnerships, adding three during the year.
MaxCyte, Inc. (NASDAQ: MXCT) announced it will release its financial results for Q4 and FY 2022 after market close on March 15, 2023. A conference call is scheduled for 4:30 p.m. ET to discuss the results. The company will also participate in investor conferences including the BIO CEO & Investor Conference on February 7, BTIG MedTech on February 14, and the Cowen Healthcare Conference on March 7. MaxCyte focuses on cell-engineering technologies to support the development of cell therapies, leveraging its proprietary Flow Electroporation platform and ExPERT family of products for innovative research in the cell therapy sector.
MaxCyte (Nasdaq: MXCT) has announced a strategic platform license with Catamaran Bio, enabling the latter to use MaxCyte's Flow Electroporation® technology and ExPERT™ platform. This collaboration will enhance Catamaran's TAILWIND® platform for developing CAR-NK cell therapies targeting solid tumors. MaxCyte expects to receive licensing fees and program-related revenue as a result. This agreement marks MaxCyte's 19th strategic platform license and aims to advance innovative cell-based cancer treatments.
MaxCyte has signed a strategic platform license with Curamys for its Flow Electroporation® technology and ExPERT™ platform, enhancing Curamys’ cell fusion technology aimed at treating rare diseases like Duchenne muscular dystrophy and amyotrophic lateral sclerosis.
Under this non-exclusive agreement, MaxCyte will receive licensing fees and program-related revenue. Curamys aims to leverage this technology to further its global reach and improve treatment options for patients with genetic disorders.
MaxCyte reported a 22% year-over-year growth in core business revenue for Q3 2022, reaching $10.6 million, a 5% increase from the prior year. Revenue from cell therapy grew by 27%, while drug discovery revenues rose 4%. The company reaffirmed its 2022 revenue guidance for core business growth at approximately 30%. Total cash and short-term investments stood at $232.9 million as of September 30, 2022. Despite strong revenue growth, operating expenses increased significantly, contributing to a net loss of $6.4 million.
MaxCyte, focused on cell-engineering, announced participation in two upcoming investor conferences. The Stifel Healthcare Conference is scheduled for November 16, 2022, at 3:00 PM ET, followed by the Stephens Annual Investment Conference on November 17, 2022, at 10:00 AM ET. Webcasts of these events will be accessible on the company’s investor relations website. MaxCyte develops technologies for cell-based therapeutics, including its proprietary Flow Electroporation® technology and ExPERT™ platform, aimed at supporting the cell therapy market.
MaxCyte, a leading commercial cell-engineering company, announced it will release its financial results for Q3 2022 after the U.S. market close on November 9, 2022. The company will host a conference call at 4:30 p.m. ET to discuss the results. MaxCyte's proprietary Flow Electroporation platform enables advanced cell-based research and therapeutic development, supporting the rapidly growing cell therapy market. The ExPERT platform is integral to their offerings, which includes various instruments and a comprehensive intellectual property portfolio.
MaxCyte has signed a strategic platform license agreement with Vertex Pharmaceuticals to use its Flow Electroporation® technology and ExPERT™ platform for the development of exa-cel, a gene-edited therapy for hemoglobinopathies.
This collaboration allows Vertex to obtain clinical and commercial rights, while MaxCyte receives licensing fees and program-related revenue. Exa-cel aims to treat transfusion-dependent beta thalassemia and sickle cell disease, showcasing the effectiveness of MaxCyte's technology utilized in previous clinical developments.
MaxCyte, a leading cell-engineering company, has relocated its headquarters to a new 67,000 square-foot facility in Rockville, Maryland, enhancing its manufacturing capacity and research capabilities. This move reflects the company’s commitment to supporting the growth of cell-based therapies and aligns with Maryland's status as a significant biotech hub. With a focus on innovation in gene editing and immuno-oncology, MaxCyte aims to empower its partners in therapeutic development and commercialization.
MaxCyte, a leader in cell-engineering, announced its participation in the Morgan Stanley 20th Annual Global Healthcare Conference on September 13, 2022, at 4:40 PM ET. The event will provide insights into the company's innovative cell-based research and cell therapeutic advancements. A live and archived webcast will be accessible on the MaxCyte investor relations website.
MaxCyte's Flow Electroporation® platform and ExPERT™ platform are pivotal in advancing cell therapies, enhancing capabilities from discovery through commercialization.
FAQ
What is the current stock price of Maxcyte (MXCT)?
What is the market cap of Maxcyte (MXCT)?
